Dhanraj Deshmukh serves on the Office of Technology Development’s Product Development team as a Pharmacology & Toxicology Associate.  He joined Memorial Sloan Kettering in 2020. 

Previously, Dhanraj was working as a Toxicology Scientist at Takeda Pharmaceutical Company Ltd. Dhanraj is board-certified (Diplomate, American Board of Toxicology) with more than nine years of experience in nonclinical safety assessment of small molecules, biologics, gene therapies, and vaccines, across multiple therapeutic areas including hematology, metabolic disorders, CNS, and infectious diseases.

Dhanraj received his PhD in Toxicology – Molecular and Mechanistic Toxicology from University of Maryland Baltimore in 2017. As a graduate student, he worked on identifying p27Kip1 as a substrate for the ubiquitin E3 ubiquitin ligase RNF6 that interacts with p27, ubiquitinating it and leading to its degradation in the early G1 phase of the cell cycle in prostate cancer cells.  He graduated from The Tamil Nadu Dr. M.G.R. Medical University with a Master’s degree in Pharmacology in 2004 and an undergraduate degree in Pharmaceutical Sciences from the Dr. B.A.M. University in 2001.